Mirtazapin Grindeks (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Grindeks, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed to treat major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality across multiple markets. Our global distribution network ensures timely delivery and compliance with local import requirements. We work closely with healthcare providers to meet their therapeutic needs.

Mirtazapine is an antidepressant that acts on serotonergic and noradrenergic pathways to improve mood in depressive disorders. - Major depressive disorder: reduces depressive symptoms and improves overall mood. - Depression with insomnia: helps alleviate depressive symptoms while improving sleep quality. - Depression with anxiety: alleviates depressive symptoms and reduces associated anxiety.

Mirtazapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling of sleepiness or fatigue. - Increased appetite: heightened hunger leading to weight gain. - Dry mouth: reduced salivation causing oral dryness. - Constipation: slowed intestinal transit. - Dizziness: light‑headed sensation, especially when standing. - Edema: mild swelling of ankles or feet. - Weight gain: notable increase in body weight. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Seizures: occurrence of convulsive episodes. - Severe hypersensitivity: rash, swelling, or anaphylaxis. - Hepatotoxicity: liver enzyme elevations or injury. - Serotonin syndrome: potentially life‑threatening condition with agitation, hyperthermia, and neuromuscular abnormalities.

When prescribing mirtazapine, clinicians should consider several safety measures and patient factors. - Assess depression severity: evaluate risk of suicide and need for close monitoring. - Monitor weight and metabolic parameters: due to risk of weight gain and increased appetite. - Caution in hepatic impairment: adjust use if liver function is compromised. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Use cautiously in elderly: increased sensitivity to sedation and falls. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Mirtazapine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis and serotonin syndrome; must be discontinued at least 14 days before starting mirtazapine. - CNS depressants: additive sedation and respiratory depression when combined with alcohol, benzodiazepines, or opioids. - Strong CYP1A2 inhibitors: may increase mirtazapine plasma levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce mirtazapine concentrations, decreasing effectiveness. - Serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increase risk of serotonin syndrome; monitor for symptoms. - Anticholinergic drugs: may exacerbate dry mouth and constipation.